Richard Koya to Melanoma
This is a "connection" page, showing publications Richard Koya has written about Melanoma.
Connection Strength
2.088
-
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
Score: 0.314
-
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684.
Score: 0.115
-
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41.
Score: 0.095
-
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56.
Score: 0.094
-
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65.
Score: 0.089
-
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
Score: 0.087
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
Score: 0.087
-
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014 Jan 01; 74(1):153-161.
Score: 0.087
-
Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.
Score: 0.086
-
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29.
Score: 0.083
-
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
Score: 0.082
-
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22.
Score: 0.078
-
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24.
Score: 0.077
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
Score: 0.077
-
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9.
Score: 0.073
-
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 2011 Feb 15; 71(4):1406-17.
Score: 0.071
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.
Score: 0.070
-
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011 Feb; 131(2):453-60.
Score: 0.070
-
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711.
Score: 0.070
-
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39.
Score: 0.068
-
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35.
Score: 0.063
-
CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70.
Score: 0.060
-
Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer. 2001 Sep; 93(6):773-80.
Score: 0.037
-
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32.
Score: 0.022
-
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.
Score: 0.018
-
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47.
Score: 0.017